Novartis books multimillion-dollar sales of Genmab-developed drug in Q1

Novartis’s sales of Kesimpta, a sclerosis drug developed by Genmab, are up by 290 percent in the first quarter of 2022 compared to Q1 2021.
Photo: ARND WIEGMANN/REUTERS / X90184
Photo: ARND WIEGMANN/REUTERS / X90184
by christian bundgaard, translated by daniel pedersen

Swiss Novartis has lit a fire under its sales of Genmab-developed multiple sclerosis drug Kesimpta, evidenced by Novartis’s financial report for the first quarter of the year.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading